Velbastine Dosage/Direction for Use

There are variations in the depth of the leukopenic response that follows therapy with Vinblastine sulfate. For this reason, it is recommended that the drug be given no more frequently than once every 7 days. It is wise to initiate therapy for adults by administering a single intravenous dose of 3.7 mg/m² of body surface area (BSA); the initial dose for children should be 2.5 mg/m². Thereafter, white-blood counts should be made to determine the patient's sensitivity to Vinblastine sulfate (see Table).

Click on icon to see table/diagram/image

For the adult patients, this dosage will be 5.5 mg/m²-7.4 mg/m². However, the dosage should be carefully considered according to a patient's clinical response (tolerance to vinblastine, hematologic response, etc) in order to obtain maximum therapeutic effect and minimal side effect.
A reduction of 50% in the dose of Vinblastine sulfate is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.
Prolonged chemotherapy for maintaining remissions involves several risks such as life-threatening infections, sterility and possibly the appearance of other cancers through suppression of immune response.